NCT04472858 - A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Advanced Solid Tumor

Interventions

DRUG

Donafenib

dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.

DRUG

CS1001

CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days

Trial Locations (1)

Unknown

RECRUITING

Shanghai Eastern Hospital, Shanghai